AstraZeneca Korea “Provides new treatment options to improve the survival rate of heart failure patients”
The first SGLT-2 inhibitor used to treat chronic heart failure with decreased left ventricular contractile function
AstraZeneca Korea’s SGLT-2 inhibitor series type 2 diabetes treatment Posiga (ingredient name: dapagliflozin) was approved by the Ministry of Food and Drug Safety to add an indication for chronic heart failure treatment on December 22nd.
According to the additional indications, Posiga can be used for the treatment of chronic heart failure patients 18 years of age or older with reduced left ventricular contractile function. This makes Posiga the first SGLT-2 inhibitor used as a treatment for heart failure with or without diabetes.
Heart failure is a disease in which the body cannot supply the amount of blood necessary for metabolism in the body due to decreased heart function. The goal of heart failure treatment is ▲improving the clinical condition of heart failure patients ▲improving the range of functions and quality of life of the patient ▲preventing hospitalization and reducing mortality.
As drugs for improving the survival rate, renin-angiotensin blockers and beta blockers are being used.
The DAPA-HF study was the basis for the addition of the indication for the treatment of heart failure in Posey. The DAPA-HF study was conducted on a total of 4744 patients with chronic heart failure (NYHA functional class II to IV) with decreased left ventricular contractile function (left ventricular ejection rate’LVEF’ 40% or less) regardless of type 2 diabetes. About 55% of all patients were patients without type 2 diabetes. In addition, more than 94% of patients were taking renin-angiotensin blockers, and more than 96% of patients were taking beta blockers.
As a result of the DAPA-HF study, Posiga reduced the risk of exacerbation of heart failure and death from cardiovascular disease, the primary endpoint, by 26% compared to placebo. In addition, the risk of death from all causes and cardiovascular death were both reduced by 17% and 18% compared to placebo, respectively.
In particular, in the group of patients without type 2 diabetes, the risk of deteriorating heart failure and death due to cardiovascular disease was lowered by 27% compared to placebo, confirming that it is effective for heart failure regardless of diabetes.
The safety profile of Fociga confirmed in the DAPA-HF study was consistent with the previous studies.
Shim Il, Managing Director of AstraZeneca Korea (CVRM Division), said, “Forsyga can provide a new treatment option that can improve the survival rate of heart failure patients.” “It will be an important starting point for presenting a milestone for SGLT-2 inhibitors that are expanding as treatments for heart failure.”
Copyright holder © The Unauthorized Reproduction and Redistribution of the Medical Hyeopsis is prohibited.